Latest Cachexia Stories
LUGANO, Switzerland and SINGAPORE, March 26, 2015 /PRNewswire/ -- This exclusive agreement broadens Helsinn's existing partnerships for anamorelin in the area of cancer
DALLAS, March 3, 2015 /PRNewswire/ -- ReportsnReports.com offers Cancer Cachexia - Pipeline Review, H1 2015 research report that provides an overview of the Cancer Cachexia's
LUGANO, Switzerland, October 30, 2014 /PRNewswire/ -- In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue
Scientists have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear.
LUGANO, Switzerland, September 27, 2014 /PRNewswire/ -- The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily
LUGANO, Switzerland, September 25, 2014 /PRNewswire/ -- Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest
AUSTIN, Texas, Sept.
New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death.
LUGANO, Switzerland, June 30, 2014 /PRNewswire/ -- Exclusive distribution and licensing agreement signed for the commercialization of Helsinn's compound currently in development